Search - tctmd.com

Displaying 41 - 60 of 9029

Sort: Relevancy | Date

News Daily News

Good News for Intravascular Imaging Continues at 5 Years: RENOVATE-COMPLEX-PCI

Caitlin E. Cox

March 10, 2026

News Conference News CRT 2026

DOBERMANN: Dobutamine and Tocilizumab Show Promise in Pre-Shock Patients

L.A. McKeown

March 09, 2026

News Daily News

Digital Data May Sway Intensive BP Treatment in the Elderly

L.A. McKeown

March 09, 2026

News Daily News

Many PE Teams Embraced Mechanical Thrombectomy Early On: PERT Registry

L.A. McKeown

March 06, 2026

News Conference News THT 2026

Baroreflex Activation for Advanced HF Yields Positive Results: Postmarketing Data

Todd Neale

March 05, 2026

News Daily News

HBR Common, Impactful Among All-Comer Acute MI Patients

Yael L. Maxwell

March 05, 2026

News Conference News THT 2026

Optimal BP After HeartMate 3 LVAD May Be Higher Than Previously Thought

Todd Neale

March 04, 2026

News Conference News CRT 2026

CRT 2026: What to Expect in Washington, DC

L.A. McKeown

March 04, 2026

News Conference News THT 2026

NT-proBNP Provides Info on Who Will Fare Well After Tricuspid TEER

Todd Neale

March 04, 2026

Presentation THT 2026

How Will Guideline Committees View Results From RWE Trials?

Presenter: Paul Heidenrich

March 04, 2026

Presentation THT 2026

Virtual Randomized Clinical Trials: Learnings From DANLOGIC-HF

Presenter: Tor Biering-Sørensen

March 04, 2026

Presentation THT 2026

Real World Databases: What Is Required for Their Use To Substitute for Randomized Trials for Device Approvals, Reimbursement and Label Expansion

Presenter: Robert W. Yeh

March 04, 2026

Presentation THT 2026

Time for a Separate Guideline Path for HF Devices?

Presenter: Javed Butler

March 04, 2026

Presentation THT 2026

Revisiting Surrogate Endpoints in Clinical Trials of HF Devices

Presenter: James Januzzi

March 04, 2026

Presentation THT 2026

The Elephant in the Room: How To Deal With PROs in Non-Sham Controlled Studies

Presenter: Gregg W. Stone

March 04, 2026

Presentation THT 2026

Revisiting Patient Reported Outcomes — Can they Be Improved for Device Trials and Account for Mortality?

Presenter: John A. Spertus

March 04, 2026

Presentation THT 2026

The Path Most Traveled: An Overview of the Breakthrough Device Designation — Can It Be Improved?

Presenter: JoAnn Lindenfeld

March 04, 2026

Presentation THT 2026

Serial Echocardiography After Greater Splanchnic Nerve Ablation In Hfpef Demonstrates Reductions In LV Filling Pressures In Clinical Responders But Not In Nonresponders: 12 Month Follow Up In The REBALANCE-HF Trial

Presenter: Sheldon E. Litwin

March 04, 2026

Presentation THT 2026

Design and Conduct of the INNOVATE Trial: Randomizing Durable LVAD Therapy in a High-Acuity Era

Presenter: Francis D. Pagani

March 04, 2026

Presentation THT 2026

The Effects Of Istaroxime In Patients With Acute Heart Failure (AHF) And Cardiogenic Shock (CS) – Combined Analysis Of 5 Phase 2 Placebo Controlled Clinical Trials

Presenter: Beth A. Davison

March 04, 2026

Advertisement

Good News for Intravascular Imaging Continues at 5 Years: RENOVATE-COMPLEX-PCI

DOBERMANN: Dobutamine and Tocilizumab Show Promise in Pre-Shock Patients

Digital Data May Sway Intensive BP Treatment in the Elderly

Many PE Teams Embraced Mechanical Thrombectomy Early On: PERT Registry

Baroreflex Activation for Advanced HF Yields Positive Results: Postmarketing Data

HBR Common, Impactful Among All-Comer Acute MI Patients

Optimal BP After HeartMate 3 LVAD May Be Higher Than Previously Thought

CRT 2026: What to Expect in Washington, DC

NT-proBNP Provides Info on Who Will Fare Well After Tricuspid TEER

How Will Guideline Committees View Results From RWE Trials?

Virtual Randomized Clinical Trials: Learnings From DANLOGIC-HF

Real World Databases: What Is Required for Their Use To Substitute for Randomized Trials for Device Approvals, Reimbursement and Label Expansion

Time for a Separate Guideline Path for HF Devices?

Revisiting Surrogate Endpoints in Clinical Trials of HF Devices

The Elephant in the Room: How To Deal With PROs in Non-Sham Controlled Studies

Revisiting Patient Reported Outcomes — Can they Be Improved for Device Trials and Account for Mortality?

The Path Most Traveled: An Overview of the Breakthrough Device Designation — Can It Be Improved?

Serial Echocardiography After Greater Splanchnic Nerve Ablation In Hfpef Demonstrates Reductions In LV Filling Pressures In Clinical Responders But Not In Nonresponders: 12 Month Follow Up In The REBALANCE-HF Trial

Design and Conduct of the INNOVATE Trial: Randomizing Durable LVAD Therapy in a High-Acuity Era

The Effects Of Istaroxime In Patients With Acute Heart Failure (AHF) And Cardiogenic Shock (CS) – Combined Analysis Of 5 Phase 2 Placebo Controlled Clinical Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content